Literature DB >> 15162523

Effect of phosphorus-32 glass microspheres on human hepatocellular carcinoma in nude mice.

Dong-Sheng Zhang1, Lu Liu, Li-Qiang Jin, Mei-Ling Wan, Qun-Hui Li.   

Abstract

AIM: To study the effects of phosphorus-32 glass microspheres ((32)P-GMS) on human hepatocellular carcinoma in nude mice.
METHODS: Human liver cancer cell line was implanted into the dorsal subcutaneous tissue of 40 BALB/c nude mice. Then the 40 tumor-bearing BALB/ c nude mice were allocated into treatment group (n=32) and control group (n=8). In the former group different doses of (32)P-GMS were injected into the tumor mass, while in the latter nonradioactive (31)P-GMS was injected into the tumor mass. The experimental animals were sacrificed on the 14th day. The ultrastructural changes of tumor in both treatment group and control group were studied with transmission electron microscopy (TEM) and stereology.
RESULTS: In treatment group, a lot of tumor cells were killed and the death rate of tumor cells was much higher (35-70%). Ultrastructurally, severe nuclear damage was observed in the death cells. The characteristics of apoptosis such as margination of heterochromatin was also found in some tumor cells. Besides, well differentiated tumor cells, degenerative tumor cells and some lymphocytes were seen. The skin and muscle adjacent to the tumor were normal. In control group, the tumor consisted of poorly differentiated tumor cells, in which there were only a few of dead cells(5%). Stereological analysis of ultrastructural morphology showed that Vv of nuclei (53.31+/-3.46) and Vv of nucleoli(20.40+/-1.84) in the control group were larger than those(30.21+/-3.52 and 10.96+/-2.52) in the treatment group respectively (P<0.01), and Vv of RER (3.21+/-0.54) and Vv of mitochondria (4.53+/-0.89) in the control group were smaller than those (8.67+/-1.25 and 7.12+/-0.95) in the treatment group respectively (P<0.01, 0.05). Sv of the membrane of microvilli and canaliculi (27.12 um(2)/100 um(3)+/-11.84 um(2)/100 um(3)) in the control group was smaller than that (78.81 um(2)/100 um(3)+/- 19.69 um(2)/100 um(3)) in the treatment group (P<0.01). But Vv of lipid particles (3.71+/-1.97) and Vv of vacuoles (5.72+/-1.58) were much larger than those (0.30+/-0.16 and 0.35+/-0.15) in the treatment group respectively (P<0.05, P<0.01).
CONCLUSION: The experimental results indicate that local administration of (32)P-GMS can produce obvious effect on liver cancer cells and the anticancer effect of (32)P-GMS is directly proportional to the dose administrated. Ultrastructural stereology can also show the effect of (32)P-GMS on the normalization of tumor cells, which is beneficial to the prognosis and treatment of patients. Moreover, local administration of (32)P-GMS is also safe.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162523      PMCID: PMC4572752          DOI: 10.3748/wjg.v10.i11.1551

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  7 in total

1.  Computed morphometric analysis and expression of alpha fetoprotein in hepatocellular carcinoma and its related lesion.

Authors:  Li-Juan Shen; Zong-Ji Zhang; Yang-Ming Ou; Hua-Xian Zhang; Run Huang; Yun He; Min-Jie Wang; Guo-Shu Xu
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma.

Authors:  Lu Liu; Zao Jiang; Gao-Jun Teng; Ji-Zhi Song; Dong-Sheng Zhang; Qing-Ming Guo; Wen Fang; Shi-Cheng He; Jin-He Guo
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

3.  Effects of hepatic arterial yttrium 90 glass microspheres in dogs.

Authors:  I Wollner; C Knutsen; P Smith; D Prieskorn; C Chrisp; J Andrews; J Juni; S Warber; J Klevering; J Crudup
Journal:  Cancer       Date:  1988-04-01       Impact factor: 6.860

4.  Toxicology of intrahepatic arterial administration of interventional phosphorus-32 glass microspheres to domestic pigs.

Authors:  L Liu; G Teng; D Zhang; J Song; S He; J Guo; W Fang
Journal:  Chin Med J (Engl)       Date:  1999-07       Impact factor: 2.628

5.  [Apoptosis induced by interstitial irradiation with 32P glass microspheres combination with hyperthermia in mouse solid tumor S180].

Authors:  Y Wang; D Wang; G Zheng; Z Mao
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2001-04

6.  Hepatic malignancies: improved treatment with intraarterial Y-90.

Authors:  M J Herba; F F Illescas; M P Thirlwell; G J Boos; L Rosenthall; M Atri; P M Bret
Journal:  Radiology       Date:  1988-11       Impact factor: 11.105

7.  Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.

Authors:  J C Andrews; S C Walker; R J Ackermann; L A Cotton; W D Ensminger; B Shapiro
Journal:  J Nucl Med       Date:  1994-10       Impact factor: 10.057

  7 in total
  4 in total

1.  Direct in vivo injection of 131I-GMS and its distribution and excretion in rabbit.

Authors:  Yu Ma; Yi Wan; Dong-Hui Luo; Li-Geng Duan; Lin Li; Chuan-Qin Xia; Xiao-Li Chen
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

2.  Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy.

Authors:  Xiao-Ming Wang; Zhen-Yu Yin; Ren-Xiang Yu; You-Yuan Peng; Ping-Guo Liu; Guo-Yang Wu
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

3.  Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells.

Authors:  Neeraj Chauhan; Amber Kruse; Hilary Newby; Meena Jaggi; Murali M Yallapu; Subhash C Chauhan
Journal:  ACS Omega       Date:  2020-01-09

4.  In vitro ultramorphological assessment of apoptosis induced by zerumbone on (HeLa).

Authors:  Siddig Ibrahim Abdel Wahab; Ahmad Bustamam Abdul; Adel Sharaf Alzubairi; Manal Mohamed Elhassan; Syam Mohan
Journal:  J Biomed Biotechnol       Date:  2009-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.